NRX Pharmaceuticals (NRXP) EPS (Basic) (2017 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly EPS (Basic) came in at -$0.18 in Q2 2026, up 13.89% year-over-year from -$0.16 in Q2 2025, and down 16.42% quarter-over-quarter from -$0.15 in Q1 2026.
Powered by 
Analysis
NRX Pharmaceuticals (NRXP) EPS (Basic) (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported EPS (Basic) for 10 consecutive years, with -$0.18 the latest figure, recorded in Q2 2026.
- On a quarterly basis, EPS (Basic) rose 13.89% year-over-year to -$0.18 in Q2 2026; TTM through Jun 2026 was -$0.56, a 23.06% increase from a year earlier, with the FY2025 full-year figure at -$0.79, up 66.58% from the prior year.
- EPS (Basic) was -$0.18 for Q2 2026 at NRX Pharmaceuticals, down from -$0.15 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.15 in Q1 2026 and troughed at -$2.47 in Q1 2022.
- A 5-year average of -$0.69 and a median of -$0.58 in 2023 frame the typical range for EPS (Basic).
- Across the five-year window, EPS (Basic) surged 98.27% in 2022 and slipped 22.95% in 2024, its largest moves.
- Over 5 years, EPS (Basic) stood at -$1.56 in 2022, then soared by 62.6% to -$0.58 in 2023, then jumped by 60.88% to -$0.23 in 2024, then declined by 8.52% to -$0.25 in 2025, then gained by 27.6% to -$0.18 in 2026.
- The last three EPS (Basic) figures came in at -$0.18 (Q2 2026), -$0.15 (Q1 2026), and -$0.25 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | NRX Pharmaceuticals | 127.63 Mn | 100.93 Mn | 426,000.00 | -0.18 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | -0.15 |
| Dec 31, 2025 | -0.25 |
| Sep 30, 2025 | -0.18 |
| Jun 30, 2025 | -0.21 |
| Mar 31, 2025 | -0.23 |
| Dec 31, 2024 | -0.23 |
| Sep 30, 2024 | -0.28 |
| Jun 30, 2024 | -0.67 |
| Mar 31, 2024 | -0.70 |
| Dec 31, 2023 | -0.58 |
| Sep 30, 2023 | -0.70 |
| Jun 30, 2023 | -1.10 |
| Mar 31, 2023 | -0.57 |
| Dec 31, 2022 | -1.56 |
| Sep 30, 2022 | -1.37 |
| Jun 30, 2022 | -1.06 |
| Mar 31, 2022 | -2.47 |
| Dec 31, 2021 | -6.48 |
| Sep 30, 2021 | -7.16 |